Beyond Cash Flows: A Multi-Agent AI Framework for Valuing Clinical-Stage, Cross-Border Biotechnology

Battle Count: 73

The paper is highly relevant to quantitative investment analysis in the biotechnology sector specifically, addressing valuation of pre-revenue, binary-event-driven assets across multiple markets. However, it is not a trading strategy paper per se—it focuses on valuation methodology and portfolio construction principles rather than signal generation, execution, or alpha capture in the traditional quant sense. The multi-agent architecture and conflict-fusion mechanism could inform quantitative decision systems, but no concrete trading signals or backtests are provided. The cross-market coordination layer has direct relevance to cross-border quantitative strategies.

The proposed framework involves multiple specialized LLM agents with domain-specific prompts, a rebuilt valuation engine using rNPV with probability-weighted binary gates, cross-market reconciliation logic, conflict-type-aware opinion fusion with iterative feedback loops, and liquidity-constrained portfolio construction. The architecture requires deep integration of scientific knowledge, regulatory expertise, multi-market data feeds, and financial modeling. Proprietary calibration parameters are withheld. The iterative bidirectional information flow between synthesizer and analyst agents adds significant orchestration complexity. No reference implementation exists.

The paper explicitly states 'no implementation is evaluated here' and 'deliberately does not disclose the proprietary parameters, weights, or implementation details that would constitute a tradeable model.' The framework is presented at architectural level only. No code, no trained model, no empirical validation of the AI system is provided. The human track record (127.17% return) is cited as evidence for the underlying method, not for any AI implementation.